Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

31 trials with published results (16%)

Research Maturity

103 completed trials (53% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.2%

10 terminated out of 194 trials

Success Rate

91.2%

+4.6% vs benchmark

Late-Stage Pipeline

8%

15 trials in Phase 3/4

Results Transparency

30%

31 of 103 completed with results

Key Signals

31 with results91% success

Data Visualizations

Phase Distribution

129Total
Not Applicable (49)
Early P 1 (3)
P 1 (23)
P 2 (39)
P 3 (13)
P 4 (2)

Trial Status

Completed103
Unknown32
Recruiting23
Active Not Recruiting14
Terminated10
Not Yet Recruiting6

Trial Success Rate

91.2%

Benchmark: 86.5%

Based on 103 completed trials

Clinical Trials (194)

Showing 20 of 20 trials
NCT07571031Not Yet RecruitingPrimary

Inter-Operator Variability in the Clinical Staging and Therapeutic Management of Basal Cell Carcinoma

NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT03521830Phase 2RecruitingPrimary

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

NCT02667574Phase 2CompletedPrimary

Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

NCT04349436Phase 1Active Not Recruiting

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

NCT05294120Phase 2Active Not RecruitingPrimary

A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma

NCT03646188Phase 1TerminatedPrimary

Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

NCT05814900Not ApplicableCompletedPrimary

Investigation of Mohs Surgical Margins Using Two Photon Microscopy

NCT05724875Not ApplicableActive Not RecruitingPrimary

FLASH Radiotherapy for Skin Cancer

NCT04480645Early Phase 1CompletedPrimary

CivaDerm(TM) Surface Therapy Pilot Study

NCT04744935Not ApplicableActive Not RecruitingPrimary

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

NCT05929664Phase 2Recruiting

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

NCT07482956Not ApplicableNot Yet RecruitingPrimary

BCC-One-Stop-Study

NCT04066504CompletedPrimary

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

NCT07241585Not ApplicableNot Yet Recruiting

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

NCT06624475Phase 2RecruitingPrimary

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

NCT07182240Not ApplicableRecruitingPrimary

Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas

NCT06422936Phase 2Active Not RecruitingPrimary

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

NCT05212246Phase 3Not Yet RecruitingPrimary

Basal Cell Carcinoma Chemoprevention Trial

NCT03889912Phase 1Completed

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Scroll to load more

Research Network

Activity Timeline